Skip to content

AMYGEPHAR: what changed

Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.

What changed

AMYGEPHAR

BE 0462.964.568
NACE 47.730, Retail sale of pharmaceutical products
financial year 2024 against 2025filed annual accounts (NBB)
Net result for the year
€18,767
2024 · €476+€18,291
Equity
€691,257
2024 · €734,157-€42,899
Cash
€24,433
2024 · €8,244+€16,189
Balance sheet total
€717,127
2024 · €749,876-€32,750

Largest movements

2024 to 2025
Assets
  • Current investments -€35,459

    down €35,459 (-7.7%), from €461,603 to €426,144

  • Receivables within one year -€16,667

    down €16,667 (-23.6%), from €70,617 to €53,950

    of which Other amounts receivable: -€14,520

  • Cash +€16,189

    up €16,189 (+196.4%), from €8,244 to €24,433

    mainly Current investments (+€35,459) and Net result for the year (+€18,767)

Equity and liabilities
  • Reserves -€43,000

    down €43,000 (-6.0%), from €714,875 to €671,875

  • Tax, wage and social debts +€13,883

    up €13,883 (+178.2%), from €7,792 to €21,675

Income statement
  • Gross operating margin +€27,067

    up €27,067, from -€16,208 to €10,859

  • Taxes +€7,484

    up €7,484 (+1728.1%), from €433 to €7,918

  • Financial income -€777

    down €777 (-3.9%), from €19,708 to €18,931

  • Depreciation +€337

    up €337 (+21.6%), from €1,565 to €1,902

  • Financial charges +€181

    up €181 (+91.0%), from €198 to €379

From the 2024 result to the 2025 result

effect on the result

Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.

Result 2024 €476
Gross operating margin +€27,067
Depreciation -€337
Other operating charges +€3
Financial income -€777
Financial charges -€181
Taxes -€7,484
Result 2025 €18,767

Cash bridge derived

cash 2024 to 2025

Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.

From operations +€42,396
Investment +€35,459
Financing -€61,666
Cash 2024 €8,244
Net result for the year +€18,767
Depreciation +€1,902
Receivables within one year +€16,667
Deferred charges and accrued income -€5,090
Trade debts -€4,904
Tax, wage and social debts +€13,883
Other debts +€1,666
Accrued charges and deferred income -€495
Current investments +€35,459
Contributions, distributions and other -€61,666
Cash 2025 €24,433
Every line side by side 41 lines
Line Code 2024 2025 Change %
Total assets 20/58 €749,876 €717,127 -€32,750 -4.4%
Fixed assets 21/28 €3,060 €1,158 -€1,902 -62.2%
Tangible fixed assets 22/27 €3,060 €1,158 -€1,902 -62.2%
Furniture and vehicles 24 €3,060 €1,158 -€1,902 -62.2%
Current assets 29/58 €746,816 €715,969 -€30,847 -4.1%
Amounts receivable after more than one year 29 €200,000 €200,000 = 0.0%
Other amounts receivable 291 €200,000 €200,000 = 0.0%
Amounts receivable within one year 40/41 €70,617 €53,950 -€16,667 -23.6%
Trade receivables 40 €24,867 €22,720 -€2,147 -8.6%
Other amounts receivable 41 €45,750 €31,231 -€14,520 -31.7%
Current investments 50/53 €461,603 €426,144 -€35,459 -7.7%
Cash at bank and in hand 54/58 €8,244 €24,433 +€16,189 +196.4%
Deferred charges and accrued income 490/1 €6,352 €11,441 +€5,090 +80.1%
Total equity and liabilities 10/49 €749,876 €717,127 -€32,750 -4.4%
Equity 10/15 €734,157 €691,257 -€42,899 -5.8%
Contributions 10/11 €18,750 €18,750 = 0.0%
Contributions outside capital 11 - €18,750 +€18,750
Other 1109/19 - €18,750 +€18,750
Reserves 13 €714,875 €671,875 -€43,000 -6.0%
Distributable reserves 133 €714,875 €671,875 -€43,000 -6.0%
Profit (loss) carried forward 14 €532 €632 +€101 +19.0%
Amounts payable 17/49 €15,719 €25,869 +€10,150 +64.6%
Amounts payable within one year 42/48 €14,726 €25,371 +€10,645 +72.3%
Trade debts 44 €6,934 €2,030 -€4,904 -70.7%
Suppliers 440/4 €6,934 €2,030 -€4,904 -70.7%
Taxes, remuneration and social security 45 €7,792 €21,675 +€13,883 +178.2%
Taxes 450/3 €7,792 €21,675 +€13,883 +178.2%
Other amounts payable 47/48 - €1,666 +€1,666
Accrued charges and deferred income 492/3 €993 €498 -€495 -49.9%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €1,565 €1,902 +€337 +21.6%
Other operating charges 640/8 €828 €825 -€3 -0.4%
Gross operating margin 9900 -€16,208 €10,859 +€27,067
Operating profit (loss) 9901 -€18,601 €8,132 +€26,733
Financial income 75/76B €19,708 €18,931 -€777 -3.9%
Recurring financial income 75 €19,708 €18,931 -€777 -3.9%
Financial charges 65/66B €198 €379 +€181 +91.0%
Recurring financial charges 65 €198 €379 +€181 +91.0%
Profit (loss) for the period before taxes 9903 €909 €26,684 +€25,775 +2836.1%
Income taxes 67/77 €433 €7,918 +€7,484 +1728.1%
Profit (loss) for the period 9904 €476 €18,767 +€18,291 +3844.9%
Profit (loss) for the period to be appropriated 9905 €476 €18,767 +€18,291 +3844.9%

Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 9 October 2026 via checked.be.